Cookies are used to help provide a better web service to patients and others.
Uses include: remembering products you add to our cart, understanding what people need and ensuring our website works properly.
Our service contains information about acquiring treatments that have been approved in another country. This includes professional information such as approval details, product information and pricing. By continuing, you are declaring that you are requesting any such information.
On June 26, 2015, the regulatory agency of Japan, the Pharmaceutical and Medical Device Agency (PMDA), has granted marketing approval for the use of Edaravone for the treatment of ALS in Japan.
The press release published by Mitsubishi Tanabe Pharma Corporation on June 26, 2015, reads the following:
"Mitsubishi Tanabe Pharma Corporation announced today that it has received approval of a partial change in manufacturing and marketing approval items related to an additional indication and dosage/usage for Amyotrophic Lateral Sclerosis (ALS) for Edaravone inj. 30mg and Edaravone bag for I.V. infusion 30mg in Japan.
Edaravone is a free-radical scavenger discovered by Mitsubishi Tanabe Pharma. In 2001, Mitsubishi Tanabe Pharma commenced clinical trials in Japan involving ALS patients. A series of clinical trials demonstrated that patients receiving Edaravone showed less functional loss than patients receiving a placebo.
Edaravone is not yet approved to treat ALS in other countries than Japan. However, Edaravone was already approved in Japan as a treatment of acute ischemic stroke. Edaravone is already available via TheSocialMedwork, and can be acquired when a doctor's prescription is provided.